Dako, Genentech Partner on Regulatory Submission of CDx for Second Breast Cancer Drug | GenomeWeb

NEW YORK (GenomeWeb News) – Dako has signed an agreement with Genentech to partner on the regulatory submission of companion diagnostic tests for a breast cancer drug.

Under the agreement announced today, the companies will collaborate on the US Food and Drug Administration submission of Dako's HercepTest and HER2 FISH pharmDx as companion diagnostics for Genentech's trastuzumab emtansine, an investigational drug candidate for patients with advanced HER2-positive breast cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.